Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2018

Open Access 09.03.2018 | Gastrointestinal Oncology

A Population-based Study on Lymph Node Retrieval in Patients with Esophageal Cancer: Results from the Dutch Upper Gastrointestinal Cancer Audit

verfasst von: L. R. van der Werf, MD, J. L. Dikken, MD, PhD, M. I. van Berge Henegouwen, MD, PhD, V. E. P. P. Lemmens, PhD, G. A. P. Nieuwenhuijzen, MD, PhD, B. P. L. Wijnhoven, MD, PhD, the Dutch Upper GI Cancer Audit group

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2018

Abstract

Background

For esophageal cancer, the number of retrieved lymph nodes (LNs) is often used as a quality indicator. The aim of this study is to analyze the number of retrieved LNs in The Netherlands, assess factors associated with LN yield, and explore the association with short-term outcomes. This is a population-based study on lymph node retrieval in patients with esophageal cancer, presenting results from the Dutch Upper Gastrointestinal Cancer Audit.

Study Design

For this retrospective national cohort study, patients with esophageal carcinoma who underwent esophagectomy between 2011 and 2016 were included. The primary outcome was the number of retrieved LNs. Univariable and multivariable regression analyses were used to test for association with ≥ 15 LNs.

Patients and Results

3970 patients were included. Between 2011 and 2016, the median number of LNs increased from 15 to 20. Factors independently associated with ≥ 15 LNs were: 0–10 kg preoperative weight loss (versus: unknown weight loss, odds ratio [95% confidence interval]: 0.71 [0.57–0.88]), Charlson score 0 (versus: Charlson score 2: 0.76 [0.63–0.92]), cN2 category (reference: cN0, 1.32 [1.05–1.65]), no neoadjuvant therapy and neoadjuvant chemotherapy (reference: neoadjuvant chemoradiotherapy, 1.73 [1.29–2.32] and 2.15 [1.54–3.01]), minimally invasive transthoracic (reference: open transthoracic, 1.46 [1.15–1.85]), open transthoracic (versus open and minimally invasive transhiatal, 0.29 [0.23–0.36] and 0.43 [0.32–0.59]), hospital volume of 26–50 or > 50 resections/year (reference: 0–25, 1.94 [1.55–2.42] and 3.01 [2.36–3.83]), and year of surgery [reference: 2011, odds ratios (ORs) 1.48, 1.53, 2.28, 2.44, 2.54]. There was no association of ≥ 15 LNs with short-term outcomes.

Conclusions

The number of LNs retrieved increased between 2011 and 2016. Weight loss, Charlson score, cN category, neoadjuvant therapy, surgical approach, year of resection, and hospital volume were all associated with increased LN yield. Retrieval of ≥ 15 LNs was not associated with increased postoperative morbidity/mortality.
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1245/​s10434-018-6396-7) contains supplementary material, which is available to authorized users.
Collaborators of the Dutch Upper Gastrointestinal Cancer group are listed in “Acknowledgment”.
Since the relationship between the number of retrieved LNs and survival was shown, the number of retrieved lymph nodes (LNs) has often been used as a quality indicator for esophageal cancer surgery.15
In 2013, the total number of retrieved LNs was introduced as one of the quality indicators in the Dutch Upper Gastrointestinal Cancer Audit (DUCA).6 This nationwide audit aims to provide insight into the quality of delivered care by reporting reliable and benchmarked information on process and outcome parameters, defined as “quality indicators.” The 7th edition of the Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) classification recommended removal of at least 15 LNs for reliable staging of gastric cancer.7 Hence, the number of 15 nodes was introduced as a quality indicator for esophageal cancer.
It is unclear whether introduction of this indicator resulted in higher LN yield. Furthermore, it is unknown which factors are associated with the number of LNs retrieved and whether higher LN yield is associated with higher postoperative morbidity or mortality.
The aim of this study is to evaluate trends in the number of retrieved lymph nodes and the proportion of patients with ≥ 15 LNs in the resection specimen. The second aim is to identify patient, tumor, and treatment factors associated with the number of retrieved LNs, LN yield, and thirdly, to evaluate whether higher LN yield is associated with increased morbidity and/or 30-day/in-hospital mortality.

Methods

Study Design

Data were retrieved from the DUCA. This surgical audit was initiated in 2011 and is part of the Dutch Institute for Clinical Auditing (DICA). All patients with esophageal or gastric cancer with intent of resection should be registered. Results on quality indicators are reported to the participating hospitals. Each year, external quality indicators are made transparent to the public, policy-makers, insurance companies, and patient federations. Validation of completeness and accuracy of data registration is performed.6 For this study, patient, tumor, and treatment characteristics, pathological information, and postoperative outcome (until 30 days after operation) were retrieved from the DUCA. Because patient and hospital identity are anonymous in the database, it was not possible to retrieve missing data or additional variables in retrospect.

Patient Selection

All patients undergoing surgery for esophageal cancer with curative intention between 2011 and 2016 were included. Patients with unknown date of birth, unknown survival status at 30 days after surgery or discharge (in case of hospital stay > 30 days), or with unknown number of retrieved LNs were excluded.
Since 2010, nCRT followed by surgery has been the standard treatment according to the Dutch guideline for esophageal carcinoma (with the exception of T1N0 tumors).8

Outcomes

Primary outcomes were the number of retrieved LNs (as documented by the pathologist based on examination of the resection specimen) and the percentage of patients with ≥ 15 LNs retrieved (as defined by the number of patients with at least 15 retrieved LNs relative to the total number of patients who underwent resection).
No informed consent or ethical approval was required under Dutch law.

Statistical Analysis

To compare patient, tumor, and treatment characteristics and surgical outcomes between the groups with ≥ 15 LNs and with < 15 LNs, the χ2 test was used. To identify associated factors, univariable and multivariable logistic regression analyses were performed. Factors with P value < 0.10 on univariable analyses or clinically relevant were included in multivariable analyses. For all analyses, statistical significance was defined as P < 0.05. All analyses were performed using SPSS® version 24 (IBM, Armonk, NY, USA) and R (R Studio, version 0.99.903, Inc., with package “ggplot2”).
Possible factors associated with LN yield were selected by the scientific committee of the DUCA based on literature. Consensus was reached for the factors age, preoperative weight loss, Body Mass Index (BMI), tumor location, American Society of Anesthesiologists (ASA) score, Charlson comorbidity score,9 clinical T-, N-, and M-category of the tumor, neoadjuvant chemo(radio)therapy, surgical approach (minimally invasive or open, and transhiatal or transthoracic), annual hospital volume, and year of surgery. For evaluation of minimally invasive approaches, stratified multivariable analysis for transhiatal and transthoracic was used. To assess the relationship between ≥ 15 LNs and surgical outcomes, yield of ≥ 15 LNs was analyzed in relation to nonradicality of the resection (resection margins not free of tumor cells), intraoperative complications, postoperative complications, and 30-day and/or in-hospital mortality. A severe complication was defined as a complication leading to hospital stay > 21 days, reintervention or death.

Results

A total of 4076 patients who underwent esophagectomy for esophageal carcinoma were registered in the DUCA between 2011 and 2016. Some patients were excluded because date of birth was missing (n = 12), survival status after 30 days/at discharge was missing (n = 80), or the number of LNs was not documented (n = 14). Hence, a total of 3970 patients was included in the study analyses (Supplementary Fig. S1).

Number of Retrieved LNs

The median number of retrieved LNs increased from 15 [interquartile range (IQR) 10–21] in 2011 to 20 (IQR 16–27) in 2016 (Fig. 1). Overall, the percentage of patients with ≥ 15 LNs was 69%. Among patients with ≥ 15 LNs, the median number of retrieved LNs was 22 (IQR 18–28), and in the group of patients with < 15 LNs, this number was 11 (IQR 8–13). The percentage of patients with ≥ 15 retrieved LNs increased from 51% in 2011 to 81% in 2016. In 2011, the percentage of patients with ≥ 15 retrieved LNs ranged between 0 and 77% among hospitals. In 2016, this variation between hospitals decreased (Fig. 2).

Factors Associated with ≥ 15 LNs

Patient, tumor, treatment, and hospital characteristics are presented in Table 1. Factors associated with < 15 LNs were Charlson score 2 (reference: Charlson score 0, 0.76 [0.63–0.92]) and unknown preoperative weight loss (reference: 0–10 kg weight loss, odds ratio [95% confidence interval] 0.71 [0.57–0.88]) (Table 2).
Table 1
Basic characteristics of study population, including score of % of patients with ≥ 15 lymph nodes for each subgroup
Patient characteristic
Total n (%)
Results on the quality indicator
< 15 LNs
≥ 15 LNs
P value*
Total
3970
31%
69%
 
 Gender
   
0.83
  Male
3077 (78%)
31%
69%
 
  Female
892 (23%)
31%
69%
 
  Unknown
1 (0.0%)
0%
100%
 
 Age (in years)
   
0.002
  0–64
1787 (45%)
29%
71%
 
  65–74
1650 (42%)
31%
69%
 
  75 +
533 (13%)
37%
63%
 
 Preoperative weight loss (kg)
   
< 0.001
  0–5
2154 (54%)
29%
71%
 
  6–10
835 (21%)
31%
69%
 
  10 +
443 (11%)
33%
67%
 
  Unknown
538 (14%)
38%
62%
 
 Body Mass Index (kg/m2)
   
0.48
  < 20
257 (6.5%)
34%
66%
 
  20–24
1512 (38%)
31%
70%
 
  25–29
1522 (38%)
30%
70%
 
  30 +
635 (16%)
33%
67%
 
  Unknown
44 (1.1%)
41%
59%
 
 Tumor location in esophagus
   
< 0.001
  Cervical
4 (0.1%)
50%
50%
 
  Proximal
40 (1.0%)
15%
85%
 
  Mid
486 (12%)
25%
76%
 
  Distal
2504 (63%)
31%
69%
 
  Gastroesophageal junction
936 (24%)
36%
65%
 
 ASA score
   
0.08
  I–II
3070 (77%)
30%
70%
 
  III +
880 (22%)
33%
67%
 
  Unknown
20 (0.5%)
50%
50%
 
 Charlson score
   
0.002
  0
1939 (49%)
29%
71%
 
  1
1012 (26%)
31%
69%
 
  2 +
1019 (26%)
35%
65%
 
 Clinical T-category
   
0.63
  cT0–1
209 (5.3%)
29%
71%
 
  cT2
736 (19%)
33%
67%
 
  cT3
2731 (69%)
31%
69%
 
  cT4
135 (3.4%)
29%
71%
 
  Unknown
159 (4.0%)
31%
69%
 
 Clinical N-category
   
0.001
  cN0
1407 (35%)
33%
67%
 
  cN1
1591 (40%)
31%
69%
 
  cN2
716 (18%)
26%
74%
 
  cN3
100 (2.5%)
25%
75%
 
  cN+ (count unknown)
42 (1.1%)
29%
71%
 
  Unknown
114 (2.9%)
45%
55%
 
 Clinical M-category
   
0.85
  cM0
3837 (97%)
31%
69%
 
  cM1
34 (0.9%)
29%
71%
 
  Unknown
99 (2.5%)
34%
66%
 
 Neoadjuvant therapy
   
0.05
  No
324 (8.2%)
28%
73%
 
  Chemotherapy
253 (6.4%)
26%
74%
 
  Chemoradiotherapy
3373 (85%)
32%
68%
 
 Surgical approach
   
< 0.001
  TTE thoracic part open
694 (18%)
27%
73%
 
  TTE thoracic part MI
1984 (50%)
18%
82%
 
  THE open
935 (24%)
56%
44%
 
  THE MI
344 (8.7%)
45%
55%
 
  Unknown
13 (0.3%)
69%
31%
 
 Salvage resection
   
0.75
  No
3870 (98%)
31%
69%
 
  Yes
55 (1.4%)
29%
71%
 
  Unknown
45 (1.1%)
29%
71%
 
 Hospital volume (average number of resections/year)
   
< 0.001
  0–25
522 (13%)
53%
47%
 
  26–50
2194 (55%)
29%
71%
 
  50 +
1229 (31%)
24%
76%
 
  Stopped before 2014
25 (0.6%)
76%
24%
 
 Year of resection
   
< 0.001
  2011
491 (12%)
50%
50%
 
  2012
613 (15%)
39%
62%
 
  2013
641 (16%)
37%
63%
 
  2014
702 (18%)
26%
74%
 
  2015
778 (20%)
24%
76%
 
  2016
745 (19%)
20%
80%
 
ASA American Society of Anesthesiologists, TTE transthoracic esophagectomy, THE transhiatal esophagectomy, MI minimally invasive, LNs lymph nodes
*Chi-squared analysis, in case of < 5% “unknown,” this category was not included in the statistical analysis (exception: cN-category)
Table 2
Multivariable logistic regression analysis for factors associated with ≥ 15 LNs
Characteristic
n
Multivariable analysis
Total
3970
P value
OR
95% CI
Age (years)
 
0.29
  
 0–64
1756
 
ref
 
 65–74
1615
0.67
0.96
0.82–1.14
 75 +
521
0.12
0.83
0.66–1.05
Preoparative weight loss (kg)
 
0.01
  
 0–10
2938
 
ref
 
 10.1–15
261
0.12
0.79
0.59–1.06
 >15
174
0.19
0.78
0.54–1.13
 Unknown
519
< 0.001
0.71
0.57–0.88
Tumor location in esophagus
 
0.59
  
 Cervical
4
0.41
0.40
0.05–3.46
 Proximal
39
0.22
1.80
0.71–4.54
 Mid
480
0.68
0.95
0.74–1.22
 Distal
2451
 
ref
 
 Gastroesophageal junction
918
0.59
1.05
0.87–1.27
ASA score
 
0.77
  
 I–II
3020
 
ref
 
 III+
872
 
1.03
0.85–1.24
Charlson score
 
0.02
  
 0
1897
 
ref
 
 1
998
0.68
0.96
0.80–1.16
 2 +
997
0.01
0.76
0.63–0.92
Clinical N-category
 
0.02
  
 cN0
1383
 
ref
 
 cN1
1553
0.37
1.08
0.91–1.29
 cN2
707
0.02
1.32
1.05–1.65
 cN3
99
0.15
1.47
0.87–2.48
 cN+ (count unknown)
41
0.30
1.50
0.70–3.19
 Unknown
109
0.07
0.67
0.43–1.03
Neoadjuvant therapy
 
< 0.001
  
 No
322
< 0.001
1.73
1.29–2.32
 Chemotherapy
249
< 0.001
2.15
1.54–3.01
 Chemoradiotherapy
3321
 
ref
 
Surgical approach
 
< 0.001
  
 TTE thoracic part open (incl. MI abdomen)
686
 
ref
 
 TTE thoracic part MI
1968
0.004
1.38
1.11–1.73
 THE open
912
< 0.001
0.29
0.23–0.36
 THE MI
326
< 0.001
0.43
0.32–0.59
Hospital volume (average number of resections/year)
 
< 0.001
  
 0–25
506
 
ref
 
 26–50
2174
< 0.001
1.94
1.55–2.42
 > 50
1212
< 0.001
3.01
2.36–3.83
Year of resection
 
< 0.001
  
 2011
462
 
ref
 
 2012
599
0.01
1.48
1.13–1.94
 2013
616
0.00
1.53
1.17–2.00
 2014
699
< 0.001
2.28
1.73–3.00
 2015
774
< 0.001
2.44
1.85–3.21
 2016
742
< 0.001
2.54
1.91–3.39
ASA American Society of Anesthesiologists, TTE transthoracic esophagectomy, THE transhiatal esophagectomy, MI minimally invasive, OR odds ratio, CI confidence interval
Factors associated with ≥ 15 LNs were clinical N2 category (reference: clinical N0, 1.32 [1.05–1.65]), no neoadjuvant therapy and neoadjuvant chemotherapy (reference neoadjuvant chemoradiotherapy, 1.73 [1.29–2.32] and 2.15 [1.54–3.01]), resection in a hospital with 26–50 or > 50 resections per year (reference: 0–25 resections, 1.94 [1.55–2.42] and 3.01 [2.36–3.83]), and resection between 2012 and 2016 (reference: 2011, ORs 1.48 [1.13–1.94], 1.53 [1.17–2.00], 2.28 [1.73–3.00], 2.44 [1.85–3.21], and 2.54 [1.91–3.39] for the years 2012 through 2016).
Transthoracic (open or minimally invasive) approach was associated with a higher percentage of patients with ≥ 15 LNs (versus open or minimally invasive transhiatal approach, 0.29 [0.23–0.36] and 0.43 [0.32–0.59]).
Stratified multivariable analysis for transthoracic resections showed a statistically significant association of minimally invasive approach with yield ≥ 15 LNs (reference: open transthoracic approach, 1.46 [1.15–1.85]). There was no such association for minimally invasive transhiatal resection with ≥ 15 LNs (reference: open transhiatal resection, 1.31 [0.97–1.75]).

LN Yield in Relation to Short-term Surgical Outcomes

Table 3 presents the association of ≥ 15 LNs with short-term outcomes (with < 15 LNs as reference group). LN yield ≥ 15 was independently associated with fewer intraoperative complications (4.5% vs. 6.8%, OR 0.69 [0.50–0.95]). Postoperative complications were more frequent in patients with ≥15 LNs than in patients with < 15 LN, but multivariable analysis showed no statistically significant association (Table 3).
Table 3
Surgical outcomes associated with ≥ 15 LNs
Outcomes
< 15 LNs % (n)
≥15 LNs % (n)
Univariable analysis
Multivariable analysis
(with outcomes as dependent variable)
OR [95% CI] ≥ 15 LNs
P value
OR [95% CI] ≥ 15 LNs
P value
Positive resection margins
5.6% (68)
4.9% (132)
1.16 [0.86–1.57]
0.33
  
Intraoperative complications
6.8% (83)
4.5% (122)
0.64 [0.48–0.86]
0.003
0.69 [0.50–0.95]^
0.02
 Bleeding (with transfusion)
22% (18)
16% (20)
    
 Intestinal injury
9.6% (8)
5.8% (7)
    
 Spleen injury
13% (11)
17% (20)
    
 Other
55% (46)
61% (75)
    
Postoperative complications
57% (702)
61% (1667)
1.17 [1.02–1.34]
0.02
1.01 [0.93–1.27]*
0.28
 Pulmonary
29% (356)
32% (879)
    
 Cardiac
12% (150)
15% (401)
    
 Anastomotic leakage/local necrosis conduit
20% (241)
18% (503)
    
 Chylous leakage
5% (58)
8% (240)
    
Severe postoperative complications
28% (339)
31% (847)
1.18 [1.01–1.37]
0.03
1.00 [0.85–1.19]*
0.98
30-day/in-hospital mortality
4.2% (52)
3.5% (95)
0.82 [0.58–1.15]
0.24
  
ASA American Surgical Association, LNs lymph nodes, OR odds ratio, CI confidence interval
^Adjusted for: Body Mass Index, ASA score, surgical approach, year of resection
*Adjusted for: age, Body Mass Index, Charlson score, ASA score, histological type, tumor location, surgical approach, hospital volume

Discussion

Between 2011 and 2016, the percentage of patients with at least 15 retrieved LNs in esophageal cancer surgery increased on a national level as well as for the individual hospitals.
Our results show an association of ≥ 15 LNs with higher clinical N-category. It may be possible that, in patients with clinically suspicious positive lymph nodes, the surgeon is particularly focused on more complete LN dissection. Also, tumor-positive LNs are often increased in size and therefore easier to identify during the operation and during pathological examination of the resection specimen. This could result in a higher number of retrieved LNs. Another explanation is that the immune response against the tumor influences the number of retrieved LNs. It has been suggested that larger tumors may cause a more intense immune response, leading to hyperplasia of local LNs, which could increase LN detectability.10 However, this hypothesis is not proven yet.
It is well known that the type of surgical approach in esophageal resection influences the number of retrieved LNs; i.e., transthoracic as compared with transhiatal approach is associated with a higher number of LNs retrieved, as also seen in the current study.11,12 Regarding the impact of a minimally invasive approach on LN yield, conflicting results have been published. A systematic review showed no differences between open and minimally invasive surgery, while another meta-analysis showed significantly higher LN retrieval in minimally invasive surgery (16 vs. 10, P = 0.03).13,14 In the present study, higher LN retrieval was seen especially in minimally invasive transthoracic procedures, which is in accordance with a recent propensity-score-matched analysis also using data from the DUCA [20 (2–59) vs. 18 (0–53) LNs; P < 0.001].15 It is possible that minimally invasive surgery offers benefits in terms of magnification and visibility of surgical structures and planes, which may translate into higher LN yield.
Busweiler et al. recently showed that, in patients undergoing gastrectomy, the percentage of patients with ≥ 15 retrieved LNs was higher in hospitals with higher composite hospital volume (gastrectomies, esophagectomies, and pancreatectomies).16 In our study, a similar association was noticed for esophageal cancer surgery. It is suggested that hospitals performing this type of surgery may benefit from the in-hospital experience.16 More intensive cooperation of a multidisciplinary team could be important for quality improvement initiatives.
This study showed an increase in the number of LNs every year. It is expected that, since the introduction of quality indicators in the DUCA, quality improvement initiatives in all hospitals have been initiated, because the results of these indicators are transparent for all individual hospitals each year. The national healthcare inspectorate, health insurance authorities, and different federations use the outcomes of this indicator to assess the quality of upper gastrointestinal surgical care in hospitals in The Netherlands. The increased numbers of retrieved LNs over the years could be the result of increased awareness of the importance of LN dissection by surgeons. On the other hand, back table dissection of the specimen and more extensive pathological assessment as a result of dedication of the pathologist could be major explanations as well. All these explanations have likely contributed to improving quality of care. The role of the pathologists in identifying nodes in the resection specimen is very important, as the time spent doing this makes a great difference.17 In this study, the role of the pathologist could not be studied, but dedicated pathologists or technicians are associated with increased number of nodes detected.18,19
More extensive LN dissection may lead to better locoregional tumor control. However, the importance of LN dissection for locoregional tumor control has been debated since the introduction of neoadjuvant chemoradiotherapy. It is known that neoadjuvant chemoradiotherapy leads to tumor and lymph node downstaging, resulting in more resections with negative margins and lymph nodes.20 The study of Talsma et al. showed that the number of retrieved LNs had a prognostic impact for patients who underwent surgery without neoadjuvant chemoradiotherapy, but not in the group of patients who underwent neoadjuvant chemoradiotherapy.21 For patients treated with neoadjuvant chemotherapy, Markar et al. also showed lower recurrence rate and improved survival for patients with higher lymph node yield. Similarly, effects of higher lymph node yield on survival or recurrence were not observed in patients treated with neoadjuvant chemoradiotherapy.22 In the current study, we observed an inverse correlation between neoadjuvant chemoradiotherapy and retrieved LNs, which has been reported before.11,21,23,24 An explanation for this phenomenon could be that use of neoadjuvant chemoradiotherapy leads to less priority for extended LN dissection by Dutch surgeons, or that neoadjuvant treatment, especially neoadjuvant chemoradiotherapy, may induce regression of LNs, as reported before.10 So, despite radical resection, fewer LNs are retrieved or detected by the pathologist. Unfortunately, the DUCA registry has no long-term follow-up. Hence, it cannot be concluded from the results of this study whether the number of retrieved LNs is a valid indicator for the quality of locoregional tumor treatment. Nonetheless, this indicator may be meaningful as an indicator for overall quality of esophageal cancer care. Higher number of retrieved LNs may lead to improved tumor staging, and complete pathological staging is essential to predict the prognosis of patients. Furthermore, in patients treated with neoadjuvant chemoradiotherapy, signs of tumor regression in LNs (instead of positive LNs) are a better predictor of prognosis than clinical N-category, which is not always easy to assess preoperatively.

Conclusions

Pro and contra arguments can be provided for use of a minimal number of retrieved LNs as a quality indicator in clinical auditing. An argument for the use of this indicator in clinical auditing is that it reveals relevant variation in outcomes of hospitals, which seems to distinguish between them. Another advantage could be that this indicator may lead to better quality of esophageal cancer because of quality improvement initiatives. However, the validity of this indicator as a direct measure of the quality of LN dissection is questionable, and the effect of more retrieved LNs on tumor control is debatable since the introduction of neoadjuvant chemoradiotherapy. Nevertheless, higher lymph node retrieval does not seem to lead to higher morbidity or mortality, so the number of retrieved LNs can safely be used as an indicator for quality of care.

Acknowledgment

The authors would like to thank all surgeons, registrars, physician assistants, and administrative nurses for data registration in the DUCA database.
Collaborators The following members of the DUCA group were collaborators in this study: K. Bosscha (Department of Surgery, Jeroen Bosch Hospital, ’s-Hertogenbosch); N. C. T. van Grieken (Department of Pathology, VU University Medical Centre, Amsterdam); H. H. Hartgrink (Department of Surgery, Leiden University Medical Centre, Leiden); R. van Hillegersberg (Department of Surgery, University Medical Centre Utrecht, Utrecht); V. E. P. P. Lemmens (Department of Epidemiology, Erasmus University Medical Centre, Rotterdam, IKNL); J. T. Plukker (Department of Surgery, University Medical Centre Groningen, Groningen); C. Rosman (Department of Surgery, Radboud University Medical Centre, Nijmegen); J. W. van Sandick (Department of Surgical Oncology, the Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam); P.D. Siersema (Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen); G. Tetteroo (Department of Surgery, IJsselland Ziekenhuis, Capelle a/d IJssel); P. M. J. F. Veldhuis (Department of Oncological Care, IKNL); F. E. M. Voncken (Department of Radiotherapy, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam).

Disclosure

The authors have declared no conflicts of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

Die Chirurgie

Print-Titel

Das Abo mit mehr Tiefe

Mit der Zeitschrift Die Chirurgie erhalten Sie zusätzlich Online-Zugriff auf weitere 43 chirurgische Fachzeitschriften, CME-Fortbildungen, Webinare, Vorbereitungskursen zur Facharztprüfung und die digitale Enzyklopädie e.Medpedia.

Bis 30. April 2024 bestellen und im ersten Jahr nur 199 € zahlen!

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Anhänge

Electronic Supplementary Material

Below is the link to the electronic supplementary material.
Literatur
1.
Zurück zum Zitat Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251(1):46–50.CrossRefPubMed Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251(1):46–50.CrossRefPubMed
2.
Zurück zum Zitat Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248(4):549–56.PubMed Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248(4):549–56.PubMed
3.
Zurück zum Zitat Dutkowski P, Hommel G, Bottger T, Schlick T, Junginger T. How many lymph nodes are needed for an accurate pN classification in esophageal cancer? Evidence for a new threshold value. Hepatogastroenterology. 2002;49(43):176–80.PubMed Dutkowski P, Hommel G, Bottger T, Schlick T, Junginger T. How many lymph nodes are needed for an accurate pN classification in esophageal cancer? Evidence for a new threshold value. Hepatogastroenterology. 2002;49(43):176–80.PubMed
4.
Zurück zum Zitat Solomon N, Zhuge Y, Cheung M, Franceschi D, Koniaris LG. The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma. Ann Surg Oncol. 2010;17(3):791–803.CrossRefPubMed Solomon N, Zhuge Y, Cheung M, Franceschi D, Koniaris LG. The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma. Ann Surg Oncol. 2010;17(3):791–803.CrossRefPubMed
5.
Zurück zum Zitat Hu Y, Hu C, Zhang H, Ping Y, Chen L-Q. How does the number of resected lymph nodes influence TNM staging and prognosis for esophageal carcinoma? Ann Surg Oncol. 2010;17(3):784–90.CrossRefPubMed Hu Y, Hu C, Zhang H, Ping Y, Chen L-Q. How does the number of resected lymph nodes influence TNM staging and prognosis for esophageal carcinoma? Ann Surg Oncol. 2010;17(3):784–90.CrossRefPubMed
6.
Zurück zum Zitat Busweiler LA, Wijnhoven BP, van Berge Henegouwen MI, et al. Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit. Br J Surg. 2016;103(13):1855–63.CrossRefPubMed Busweiler LA, Wijnhoven BP, van Berge Henegouwen MI, et al. Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit. Br J Surg. 2016;103(13):1855–63.CrossRefPubMed
7.
Zurück zum Zitat Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A. AJCC cancer staging manual. Springer, New York; 2010. Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A. AJCC cancer staging manual. Springer, New York; 2010.
8.
Zurück zum Zitat Dutch Society of Gastroenterologists. Guideline esophagus carcinoma. Version 3.1. 2015. Dutch Society of Gastroenterologists. Guideline esophagus carcinoma. Version 3.1. 2015.
9.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed
11.
Zurück zum Zitat Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–9.CrossRefPubMed Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–9.CrossRefPubMed
12.
Zurück zum Zitat Davies AR, Sandhu H, Pillai A, et al. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg. 2014;101(5):511–7.CrossRefPubMed Davies AR, Sandhu H, Pillai A, et al. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg. 2014;101(5):511–7.CrossRefPubMed
13.
Zurück zum Zitat Parry K, Ruurda JP, van der Sluis PC, van Hillegersberg R. Current status of laparoscopic transhiatal esophagectomy for esophageal cancer patients: a systematic review of the literature. Dis Esophagus. 2017;30(1):1–7.PubMed Parry K, Ruurda JP, van der Sluis PC, van Hillegersberg R. Current status of laparoscopic transhiatal esophagectomy for esophageal cancer patients: a systematic review of the literature. Dis Esophagus. 2017;30(1):1–7.PubMed
14.
Zurück zum Zitat Dantoc M, Cox MR, Eslick GD. Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg. 2012;147(8):768–76.CrossRefPubMed Dantoc M, Cox MR, Eslick GD. Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg. 2012;147(8):768–76.CrossRefPubMed
15.
Zurück zum Zitat Seesing MFJ, Gisbertz SS, Goense L, et al. A propensity score matched analysis of open versus minimally invasive transthoracic esophagectomy in the Netherlands. Ann Surg. 2017;266(5):839–46.CrossRefPubMed Seesing MFJ, Gisbertz SS, Goense L, et al. A propensity score matched analysis of open versus minimally invasive transthoracic esophagectomy in the Netherlands. Ann Surg. 2017;266(5):839–46.CrossRefPubMed
16.
Zurück zum Zitat Busweiler LA, Dikken JL, van Berge Henegouwen MI, et al. The influence of a composite hospital volume of upper gastrointestinal cancer resections on outcomes of gastric cancer surgery. J Clin Oncol. 2016;34(7_suppl):305.CrossRef Busweiler LA, Dikken JL, van Berge Henegouwen MI, et al. The influence of a composite hospital volume of upper gastrointestinal cancer resections on outcomes of gastric cancer surgery. J Clin Oncol. 2016;34(7_suppl):305.CrossRef
17.
Zurück zum Zitat de Burlet KJ, van den Hout MF, Putter H, Smit VT, Hartgrink HH. Total number of lymph nodes in oncologic resections, is there more to be found? J Gastrointest Surg. 2015;19(5):943–8.CrossRefPubMedPubMedCentral de Burlet KJ, van den Hout MF, Putter H, Smit VT, Hartgrink HH. Total number of lymph nodes in oncologic resections, is there more to be found? J Gastrointest Surg. 2015;19(5):943–8.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Kuijpers CC, van Slooten HJ, Schreurs WH, et al. Better retrieval of lymph nodes in colorectal resection specimens by pathologists’ assistants. J Clin Pathol. 2013;66(1):18–23.CrossRefPubMed Kuijpers CC, van Slooten HJ, Schreurs WH, et al. Better retrieval of lymph nodes in colorectal resection specimens by pathologists’ assistants. J Clin Pathol. 2013;66(1):18–23.CrossRefPubMed
20.
Zurück zum Zitat van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRefPubMed van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRefPubMed
21.
Zurück zum Zitat Talsma AK, Shapiro J, Looman CW, et al. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg. 2014;260(5):786–92; discussion 792–783.CrossRef Talsma AK, Shapiro J, Looman CW, et al. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg. 2014;260(5):786–92; discussion 792–783.CrossRef
22.
Zurück zum Zitat Markar SR, Noordman BJ, Mackenzie H, et al. Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study. Ann Oncol. 2017;28(3):519–27.PubMed Markar SR, Noordman BJ, Mackenzie H, et al. Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study. Ann Oncol. 2017;28(3):519–27.PubMed
23.
Zurück zum Zitat Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg. 2001;72(1):306–13.CrossRefPubMed Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg. 2001;72(1):306–13.CrossRefPubMed
24.
Zurück zum Zitat Robb WB, Dahan L, Mornex F, et al. Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial. Ann Surg. 2015;261(5):902–8.CrossRefPubMed Robb WB, Dahan L, Mornex F, et al. Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial. Ann Surg. 2015;261(5):902–8.CrossRefPubMed
Metadaten
Titel
A Population-based Study on Lymph Node Retrieval in Patients with Esophageal Cancer: Results from the Dutch Upper Gastrointestinal Cancer Audit
verfasst von
L. R. van der Werf, MD
J. L. Dikken, MD, PhD
M. I. van Berge Henegouwen, MD, PhD
V. E. P. P. Lemmens, PhD
G. A. P. Nieuwenhuijzen, MD, PhD
B. P. L. Wijnhoven, MD, PhD
the Dutch Upper GI Cancer Audit group
Publikationsdatum
09.03.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6396-7

Weitere Artikel der Ausgabe 5/2018

Annals of Surgical Oncology 5/2018 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.